DCOY

Decoy Therapeutics Inc. DCOY

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $5.2M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$227.6K

Quarter to Jun 30

Net income

$-2.37M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$31.0K total
VANGUARD CAPITAL MANAGEMENT LLC
$29.0KNew
Tower Research Capital LLC (TRC)
$1.8K-74.9%
UBS Group AG
$180-95.4%
Caitong International Asset Management Co., Ltd
$14New
See all 4 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/DCOY

Earnings Per Share

13fpro.ai/company/DCOY

Loading ratio trend…

DCOY key financials by period

Reported revenue, net income and operating margin by fiscal year, from Decoy Therapeutics Inc.'s annual filings on SEC EDGAR.

Decoy Therapeutics Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2021$1.8M$-12.8M—
FY 2020$5.2M$-7.4M-148.8%
FY 2019$3.5M$-6.9M—
FY 2018$2.0M$-1.7M-86.3%
FY 2017$1.3M$-34.4M—
FY 2016$1.0M$-39.5M—
Source: DCOY filings on SEC EDGAR →

DCOY insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Decoy Therapeutics Inc. (DCOY): stock profile, AI score and financials

Decoy Therapeutics Inc. (DCOY) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. DCOY is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $5.2m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Decoy Therapeutics Inc. reports quarterly revenue of $227.6K, net income of $-2.4M. Top institutional holders of DCOY by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, Tower Research Capital (TRC), UBS Group AG, based on the most recent SEC filings. DCOY trades on the Nasdaq exchange and files with the SEC under CIK 1615219. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DCOY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Decoy Therapeutics Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1615219 →